XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)
 6 Months Ended
Sep. 26, 2020
Segment Reporting [Abstract]  
Selected Information by Business Segment
Selected information by reportable segment is presented below:
Three Months EndedSix Months Ended
(In thousands)September 26,
2020		September 28,
2019		September 26,
2020		September 28,
2019
Net revenues
Plasma$78,718 $116,381 $147,433 $227,144 
Blood Center74,715 83,667 154,029 161,663 
Hospital51,022 49,662 96,593 96,849 
Net revenues by business unit204,455 249,710 398,055 485,656 
Service (1)
5,342 5,276 10,424 10,142 
Effect of exchange rates(311)(2,420)(3,416)(4,781)
Net revenues$209,486 $252,566 $405,063 $491,017 
(1) Reflects revenue for service, maintenance and parts
Three Months EndedSix Months Ended
(In thousands)September 26,
2020		September 28,
2019		September 26,
2020		September 28,
2019
Segment operating income
Plasma$40,823 $56,776 $77,173 $110,501 
Blood Center33,757 41,208 72,502 78,927 
Hospital21,459 20,851 39,242 39,767 
Segment operating income96,039 118,835 188,917 229,195 
  Corporate expenses (1)
(56,741)(63,580)(121,803)(125,283)
  Effect of exchange rates3,647 2,501 4,358 5,270 
  Deal amortization(8,136)(5,935)(16,399)(11,909)
  Restructuring and turnaround costs(4,440)(3,757)(8,440)(5,784)
  Transaction costs(1,773)— (3,063)— 
  PCS2 accelerated depreciation and related costs(644)(6,534)(2,186)(12,062)
  European Medical Device Regulation costs and other(736)180 (1,489)147 
  Impairment of assets and other related charges68 (54)(896)(51,220)
  Gains on divestitures and sale of assets31,498 8,083 31,498 8,083 
Operating income$58,782 $49,739 $70,497 $36,437 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Product Line and Geographic Regions Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.
Net revenues by product line are as follows:
 Three Months EndedSix Months Ended
(In thousands)September 26,
2020		September 28,
2019		September 26,
2020		September 28,
2019
Plasma products and services$97,710 $135,849 $186,423 $265,594 
Blood Center products and services59,233 65,615 119,900 125,522 
Hospital products and services52,543 51,102 98,740 99,901 
Net revenues$209,486 $252,566 $405,063 $491,017 
Net revenues generated in the Company's principle operating regions on a reported basis are as follows:
Three Months EndedSix Months Ended
(In thousands)September 26,
2020		September 28,
2019		September 26,
2020		September 28,
2019
United States$123,984 $161,880 $234,993 $318,255 
Japan19,645 20,376 36,476 35,843 
Europe38,648 38,074 81,667 74,827 
Asia26,168 30,192 48,552 58,833 
Other1,041 2,044 3,375 3,259 
Net revenues$209,486 $252,566 $405,063 $491,017